Here we identify PML as a critical inhibitor of neoangiogenesis (the formation of new blood vessels) in vivo, in both ischaemic and neoplastic conditions, through the control of protein translation.

The promyelocytic leukemia (PML) protein has been previously recognized as a critical and essential regulator of multiple apoptotic response.

PML has now affected more than 450 MS patients receiving long-term natalizumab; unfortunately, since PML is not a reportable disease, there are no exact numbers.

PML incidence is expected to decline with screening of MS patients for JC virus exposure prior to natalizumab's initiation, which has only recently become routine.

Two cases of progressive multifocal leukoencephalopathy (PML) are reported in patients with psoriasis who were treated with fumarates, one with Fumaderm and the other with a compound containing dim ...